Evolution VC Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Figure develops general-purpose humanoid robots designed for deployment in workforce and home environments.
AI & Machine LearningHardwareRoboticsSunnyvale, US
Brett Adcock(Executive Officer, Director)inLee Randaccio(Executive Officer)Dana Berlin(Executive Officer)Logan Berkowitz(Executive Officer)Colby Adcock(Director)Peter Welinder(Director)
Co-investorsAUDEO VENTURESAurum Venture PartnersBeyond CapitalBold Capital PartnersBVVCCoatue Management+25 more
Response Pharmaceuticals is a clinical-stage drug developer working on RDX-002, a small-molecule iMTP inhibitor for weight management and metabolic health, including post-GLP-1 receptor agonist weight management and antipsychotic-induced weight gain.
BiotechDigital HealthHealthtechLongevityFalls Church, US
Paul Sweetnam(Chief Scientific Officer & Co-Founder)Eric Keller(Chief Executive Officer, Founder & Chairman)John Ferkany(Founder)inWilliam Sasiela(Chief Medical Officer)inCraig M. Audet(Chief Regulatory Officer)inLiam Brenner(Chief Financial Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.